Wisconsin Act 294 – Formulary Management and Collaborative Practice Agreements in the Long-term Care Facility

Matt Palmer, PharmD, BCGP
Kim McDevitt, Student Pharmacist CUWSOP Class of 2018
Lynne Fehrenbacher, PharmD, BCPS-AQ ID

Learning Objectives

• Define Wisconsin Act 294 and describe how this legislation can improve medication management resulting in improved quality of care for Long-term Care residents.

• Describe the potential benefits and logistics of implementing formulary management and collaborative practice agreements under WI Act 294 in the Long-term Care setting.

• Review a sample collaborative practice agreement to manage antibiotic use for the treatment of urinary tract infections.
Wisconsin Act 294

Accomplished 2 main goals

1. Established the ability of nursing homes in Wisconsin to have drug formularies
2. Allowed for a physician to delegate any patient care service to a pharmacist
Drug Formularies

- Hospitals
- Health Systems
- Insurance Companies
- State Agencies - Medicaid

Why not nursing homes?

Nursing Facility Formulary

What do you need?

- Quality Assurance and Assessment (QAA) Committee that includes a pharmacist
  
  OR

- A committee that consists of a physician, director of nursing, pharmacist, and at least 2 other members of nursing home staff
### Nursing Home Formulary

- The QAA or other committee may establish written guidelines or procedures for making therapeutic alternate drug selections.
- The therapeutic alternate drug must be approved by:
  - Patient’s personal physician
  - Patient’s physician assistant

### LTC Formulary Management

#### Prescription Drugs
- Therapeutic Interchange Programs allow dispensing pharmacist to switch to formulary approved medications upon admission

#### Over the Counter Medications (OTC)
- Nursing staff can change to established therapeutic alternatives upon admission

*Both require written procedures*
### Wisconsin Healthcare-Associated Infections in LTC Coalition

#### Rx Formulary Interchange

- Crestor ➔ Atorvastatin
- Humalog ➔ Novolog
- Novolog ➔ Humalog
- Xopenex ➔ Albuterol
- Insulin vials ➔ Insulin Pens
- Lumigan/Zioptan/Travatan ➔ Latanoprost

#### OTC Formulary Examples

- Iron Preparations ➔ Ferrous Sulfate 325mg
- Calcium/Vit D Preparations ➔ Calcium carbonate 600mg with Vitamin D 400 units.
- Multivitamin Preparations
- Artificial Tears
- Probiotics
- Acetaminophen PRN orders
- Vitamin D
Benefits of Formulary Management in LTC

- Increased medication availability
- Potential to save on Medicare Part A drug spending
- Facility OTC cost reduction
  - Ingredient cost
  - Storage and ordering cost
- Safety
  - Less product variability = more familiar to nursing staff, less prone to error

Barriers to LTC Formulary

- Short Stay Residents
- MD adoption
- Pharmacy adoption
- Nursing adoption
- Large number of OTC products on the market
Questions?

Wisconsin Act 294

“A pharmacist may perform any patient care service delegated to the pharmacist by a physician”
Wisconsin Act 294

2013 Senate Bill 251
Section 4. 450.033 of the statutes is created to read:

- **450.033 Services delegated by physician.** A pharmacist may perform any patient care service delegated to the pharmacist by a physician, as defined in s. 448.01 (5).
  - "Physician" means an individual possessing the degree of doctor of medicine or doctor of osteopathy or an equivalent degree as determined by the medical examining board, and holding a license granted by the medical examining board.
    - Note lack of Nurse Practitioner guidance
Collaborative Practice Agreement

A voluntary agreement between one or more prescribers and pharmacists establishing cooperative practice procedures under defined conditions and/or limitations toward one common goal.

Goals

- Mutual goals and common direction
- Built upon trust and communication
- Shared responsibility for care
- Realistic and relevant to practice setting
- Improvement of patient outcomes
- Outlined procedures are broad in scope
Wisconsin Healthcare-Associated Infections in LTC Coalition

Framework for Successful CPAs

Align Incentives
- Patients, providers, and payers receive appropriate incentives while collaborating to advance patient's health.
  - For patients: A product, service, experience, or added value that motivates the patient to take actions that will improve health.
  - For health care providers: Appropriate compensation for products and services provided.
  - For payers: Minimizing total health care expenditures while providing high-quality, necessary services.

Improve Outcomes
- As pharmacists, patients, and others on the team work together, patient health outcomes improve.
  - Tracking progress and reporting outcomes ensures all members of the health care team involved in the patient's care are aware of the impact of the collaborative efforts.

Control Costs
- The aligned incentive for the health care system is similar to that for each payer: control overall health care costs.
  - Improved health status ultimately decreases health care costs.

Applications of a CPA

Activities covered may include:
- Immunizations
- Refill authorizations
- Therapeutic substitutions
- Screenings
- Disease state management
  - Selecting, initiating, adjusting, assessing, monitoring, or managing drug therapy.
  - Providing drug education
  - Formulating treatment plans
  - Performing comprehensive medication reviews
**Wisconsin Healthcare-Associated Infections in LTC Coalition**

## Benefits of a CPA

- **Patients**
  - Better access to care through a pharmacist
  - Reduced cost for care
- **Physicians**
  - Delegation to drug therapy experts
  - Effective use of time
  - Increased patient time with knowledgeable provider
    - Results in increased patient satisfaction
- **Pharmacist**
  - Autonomy in a patient focused practice
  - Improved patient relationships
  - Personal job satisfaction and professional growth
- **Payers**
  - Minimize total health care expenditures
  - Providing high-quality, necessary services

*Slide courtesy of Dr. Andy Traynor*

## Key Elements of CPAs

### Agreement Cover Page
- Agreement statement authorizing the CPA
- Names of individual pharmacist(s) and prescriber(s)
- Signatures of participating practitioners/directors

### Purpose/Intro
- State the purpose of the CPA or background information
- Describe the qualifications of the pharmacist(s)

### Policy Statement
- Conditions for following or not following the written protocol
- Description of Continuous Quality Improvement Program
- Process for reviewing, revising, and renewing CPA
- Methods for communicating clinical outcomes
- Terms of agreement for termination
- Prescriber monitoring and provision to intercede where necessary

*Adapted from slide developed by Dr. Andy Traynor*
### CPA Sections\(^3,6\)

#### Organization of the Service/ Protocol
- Patient referral procedures/methods
- Authority allowed
- Clinical activities performed by pharmacist
- Patient referral procedures/methods
- Services provided during a patient encounter
- Follow-up procedures to be used
- Documentation procedures

---

### CPA Sections\(^3\)

#### Appendices
- Treatment algorithms
- Educational materials
- Forms

#### References

---

Adapted from slide developed by Dr. Laura Traynor
### CPA Information

#### Resources

1. **Collaborative Practice Agreements: 2014 Implementation Toolkit**
   - Includes links to several types of CPA examples

2. **Collaborative Practice Agreements and Pharmacist’s Patient Care Services: A Resource for Pharmacists.**
   - [https://www.cdc.gov/dhdsp/pubs/docs/Pharmacist_State_Law.PDF](https://www.cdc.gov/dhdsp/pubs/docs/Pharmacist_State_Law.PDF)

3. **Improving Patient and Health System Outcomes through Advanced Pharmacy Practice. A Report to the U.S. Surgeon General.**

4. **ACCP: Collaborative Practice Agreements in Outpatient Team-Based Clinical Pharmacy Practice**

5. **The expanding role of pharmacists in a transformed health care system.**

6. **ACCP: Collaborative Drug Therapy Management and Comprehensive Medication Management 2015**
10 Elements of a CPA:

1. Identification of the Practitioner(s) and Pharmacist(s) who are parties to the Agreement;
2. Types of decisions the Pharmacist is allowed to make;
3. A process for generating any medical/prescription orders that are required to initiate allowed activities;
4. A method for the Practitioner to monitor compliance with the Agreement and clinical outcomes and to intercede when necessary;
5. A description of the Continuous Quality Improvement Program used to evaluate the effectiveness of patient care and ensure positive patient outcomes;
6. A provision that allows the Practitioner to override a Collaborative Practice decision made by the Pharmacist whenever he or she deems it necessary or appropriate;
7. A provision that allows either party to cancel the Agreement by written notification.
10 Elements of a CPA:

8. An effective date

9. Signatures of all collaborating Pharmacists and Practitioners who are party to the agreement, as well as dates of signing

10. A procedure for periodic review and renewal within a time frame that is clinically appropriate.

CPA Question 1

The National Association of Boards of Pharmacy (NABP) lists 10 elements of a CPA. Which of the following is not an example of one of the 10 elements?

A. An effective date & date of participator signatures

B. A provision that allows a third party to cancel the Agreement by verbal notification

C. A description of the Continuous Quality Improvement Program

D. Types of decisions the Pharmacist is allowed to make
**CPA Question 1: Answer**

The National Association of Boards of Pharmacy (NABP) lists 8 elements of a CPA, which of the following is not an example of one of the 10 elements?

A. An effective date & date of participator signatures

B. **A provision that allows a third party to cancel the Agreement by verbal notification**

C. A description of the Continuous Quality Improvement Program

D. Types of decisions the Pharmacist is allowed to make

**CPA Question 2**

Clinical pharmacist involvement in patient care can improve quality and safety measures that are increasingly tied to reimbursement. Which of the following are examples quality measures?

A. Appropriateness of treatment

B. Timeliness of treatment

C. Communication with patients about their medications

D. All of the above
CPA Question 2: Answer

Clinical pharmacist involvement in patient care can improve quality and safety measures that are increasingly tied to reimbursement. Which of the following are examples quality measures?

A. Appropriateness of treatment
B. Timeliness of treatment
C. Communication with patients about their medications
D. All of the above

CPA Question 3

All of the following are potential examples of delegated pharmacist authority under a CPA except?

A. Formulating treatment plans
B. Selecting, initiating, adjusting, assessing, monitoring or managing drug therapy
C. Diagnosing a patient and prescribing treatment for therapy
D. Selecting therapeutic substitutions
CPA Question 3: Answer

All of the following are potential examples of delegated pharmacist authority under a CPA except?

A. Formulating treatment plans
B. Selecting, initiating, adjusting, assessing, monitoring or managing drug therapy
C. Diagnosing a patient and prescribing treatment for therapy
D. Selecting therapeutic substitutions

CPA Question 4

True or False:

Amendments to a Collaborative Practice Agreement must be documented, signed, and dated.
Amendments to a Collaborative Practice Agreement must be documented, signed, and dated.

TRUE!
Antibiotic use in Nursing Homes\textsuperscript{7–9}

47 - 79\% of nursing home residents receive antibiotics each year, and

77 - 88\% of all infectious episodes are prescribed antibiotics.

This overuse of antibiotics leads to numerous complications including:

- Drug interactions
- Antimicrobial resistance
- Adverse effects
- Allergies
- Increased rates of \textit{Clostridium difficile}

Antibiotic use in Nursing Homes\textsuperscript{10,11}

Up to 80\% of all antibiotic use is inappropriate in nursing homes.
What are all these antibiotics prescribed for?\textsuperscript{12}

Examples of clinical situations in LTC for which antibiotics are often prescribed, but rarely necessary:

- **Urinary Tract Infections**
- Upper Respiratory symptoms
- Viral Respiratory infections
- Skin Wounds

At least 30% of all antibiotics prescribed in LTC are for treating UTIs, the most common reason for an antibiotic order in LTCFs.

Urinary Analysis and Antibiotic use?

- If we tested the urine of everyone in our LTC facility for a UTI what percentage would be positive for bacteria?

25%? 50%? 75%?!

- What usually happens when a physician gets a fax with a “positive urine culture?”
Wisconsin Healthcare-Associated Infections in LTC Coalition

Centers for Medicare & Medicaid Services (CMS):
State Operations Manual

**F329: Unnecessary Medications**

"Review whether the resident is receiving any medications without an indication for use, in excessive dose or duration, with inadequate monitoring, or in the presence of any adverse consequences that indicate that the dose should be reduced or discontinued."

**WI 2015 F329 Violations**

**134 Total**

- 51 were related to the treatment of asymptomatic bacteriuria
- 21 instances of not collecting cultures or not waiting for culture results in the absence of warning signs before starting antibiotics
- 14 antibiotics given when sensitivities indicated the bacteria was resistant
- 3 examples of antibiotic prophylaxis for UTI

44 citations (89 examples) related to antibiotics and UTI !!!
CMS “Mega Rule”

- Nursing homes will be required to have an Antibiotic Stewardship Program
- CMS encourages facilities to collaborate with their pharmacist
- “we encourage the QAA Committee to collaborate with the pharmacist to enhance the committee’s understanding and oversight of the facility’s pharmaceutical practices, especially concerning the use of psychotropic drugs and its antibiotic stewardship, as well as their QAPI activities”

§ 483.45 & “irregularities”

(d) Unnecessary drugs—General.
Each resident’s drug regimen must be free from unnecessary drugs. An unnecessary drug is any drug when used—
(1) In excessive dose (including duplicate drug therapy); or
(2) For excessive duration; or
(3) Without adequate monitoring; or
(4) Without adequate indications for its use; or
(5) In the presence of adverse consequences which indicate the dose should be reduced or discontinued; or
(6) Any combinations of the reasons stated in paragraphs (d)(1) through (5) of this section.
§ 483.45 (c)(4)\textsuperscript{14}

(ii) Any irregularities noted by the pharmacist during this review must be documented on a separate, written report that is sent to the attending physician and the facility’s medical director and director of nursing and lists, at a minimum:

- the resident’s name
- the relevant drug, and
- the irregularity the pharmacist identified.

§ 483.45(c)(4)(iii)\textsuperscript{14}

• Requires the attending physician to document in the resident’s medical record that the (pharmacist) identified irregularity has been reviewed and what, if any, action has been taken to address it.

• If there is to be no change in the medication, the attending physician should document his or her rationale in the resident’s medical record.
UTI Collaborative Practice Agreement

What’s the Point?

To optimize antimicrobial use for the treatment of UTIs in LTC facilities

Antibiotic Stewardship Goal

“Optimize the treatment of infections while reducing the adverse events associated with antibiotic use”
– CDC Core Elements
Implementation

“Do you have a policy for that?”

Potential Goals of a UTI CPA

- Optimize antimicrobial use, including agent selection, dose, and duration, for our residents
- Reduce unnecessary use of antimicrobials in our residents
- Facilitate appropriate monitoring and dose adjustment of antimicrobials for our residents
- Reduce the risk of adverse drug events in our residents
- To mitigate risk for development of multi-drug resistant organisms in our facility
Sample Nursing Home Policy

Please see handout

UTI Treatment CPA Draft

Please see handout to follow along
The Wisconsin Medical Practice Act Section 448.03(2)(e) allows pharmacists to practice under a Collaborative Practice Agreement with individual physician(s) who is/are responsible for the patient’s care and authorized to prescribe drugs. Through this agreement, pharmacists may participate in the practice of managing and modifying drug therapy. It is the intent of this document to authorize the pharmacist(s) listed below to work in a collaborative fashion with the physician(s) listed below. The document sets forth guidelines for collaboration between the physician(s) and pharmacist(s). This agreement is voluntary and may be terminated at any time by either party.

Purpose/Background
In order to enhance collaborative patient care, optimize antimicrobial stewardship and safety for medications being used to treat lower urinary tract infections. Pharmacists will be delegated authority by participating physicians to independently manage and/or modify antimicrobial therapy and order select labs as outlined in the agreement.

Policy
Pharmacist(s) will adhere to this agreement. This agreement applies to residents under the care of providers at
Activities performed by the clinical pharmacist under the collaborative practice agreement with the physician(s) for purposes of medication therapy management may include:

- Order a basic metabolic panel (BMP) to obtain serum creatinine (SCr) if one is not available from the past 30 days.
- If not already ordered, may order an International Normalized Ratio (INR) for residents on warfarin therapy to monitor for drug-drug interactions both during and at an appropriate interval post antibiotic discontinuation.
- If not already ordered, may order a urinalysis with culture and sensitivity if indicated, for the purpose of targeting antibiotic therapy.
- Calculate the resident’s estimated CrCl using the Cockcroft-Gault Equation and adjust urinary tract antibiotic dose per CrCl recommendations in Table 1.

Adjust antibiotic selection if it is contraindicated, has potential for significant drug interaction(s), adverse drug event(s), or is not recommended for use through reference of current clinical practice guidelines, professional judgement, or resources contained within this agreement.

The following component(s) of the CPA is/are authorized if the corresponding box is checked:

- The pharmacist may discontinue an ORAL antibiotic in an ASYMPTOMATIC patient with negative urinalysis and/or culture (<100,000 CFU/ml). Discontinuation of IV therapy requires discussion with the prescribing provider.
Organization (continued)

- If a patient is on an ORAL antibiotic and another ORAL antibiotic of narrower spectrum will treat the organism, the pharmacist may de-escalate an antibiotic prescribed per culture and sensitivity data.

- If the patient is on an empiric ORAL antibiotic and sensitivity data reveals resistance to prescribed empiric ORAL therapy, the pharmacist may change the antibiotic prescribed if another ORAL antibiotic option is available. If IV therapy is identified as necessary, the pharmacist is required to contact the prescribing provider to discuss the patient case and obtain a new order.

Documentation:
All activities will be documented in the resident’s record and will be available for review.

Quality Improvement

- Clinical activities related to this agreement will be reviewed at least annually by the clinical pharmacist and physician providers, and revised as needed.

Clinical Pharmacist Qualifications:

- Active pharmacist licensure in good standing in the state of Wisconsin.
UTI CPA Examples

Goal:
Identify positive resident and facility outcomes.

Consider:
How would a physician and pharmacist CPA for UTI treatment benefit the following patients in the depicted cases?

Case #1
- Resident MP is diagnosed with a UTI and starting antibiotic therapy with Bactrim DS.
- MP is currently taking warfarin, and most recent labs were taken three months ago.

Necessary actions:
- Ensure proper renal dosing of Bactrim.
- Acquire international normalized ratio (INR) to monitor for drug interaction.
Case #1

**Pharmacist actions:**
- Order labs for renal dosing adjustment per CPA.
- Acquire international normalized ratio (INR) for monitoring of drug interaction.

**Clinical benefit:**
- Safety
  - Decreased risk for TMP/SMX toxicities
  - Decreased risk for bleeding with INR check

KM Case #2

- Resident KM is diagnosed with a UTI and starting antibiotic therapy with ciprofloxacin.

**Pharmacist actions:**
- Renal function assessment
- Review for alternative antibiotics – allergies and renal function don’t allow for a change
- Decrease dose based on renal function
KM Case #2

Clinical benefit:

• Safety
  o Ensuring quinolone used only if no other option (FDA advisory)
  o Decreased risk of quinolone toxicities
    ▪ Arrhythmias
    ▪ Muscle and tendon effects

TC Case #4

• Resident TC returned from the ER after an evaluation for a fall. ER diagnosis is UTI with orders for ciprofloxacin 250mg po BID

Pharmacist action:
  ✓ Discontinue Ciprofloxacin
Clinical benefits:

- Safety
  - Prevention of antibiotic exposure (resistance)
  - Avoidance of quinolone use (FDA advisory)
  - Decreased risk of quinolone toxicities
    - Arrhythmias and drug interactions
    - Muscle and tendon effects
  - Decreased risk for *C. diff* by discontinuing broad spectrum antibiotic

Clinical benefits (continued):

- Cost
  - Antibiotic was discontinued
  - Potential cost-avoidance for secondary infection (*C. diff*)
- Regulatory
  - F329 avoided
• Resident MM diagnosed with UTI and started on nitrofurantoin, switched to TMP/SMX as symptoms unresolved. C&S results are reviewed by the pharmacist per CPA protocol

Pharmacist action:
✓ Change TMP/SMX to Ciprofloxacin 250mg PO BID x 7 days

Clinical benefits:
• Safety/Cost
  o Prevented antibiotic treatment failure and potential hospitalization
• Regulatory
  o F329 prevented
PK Case #7

- Resident PK diagnosed with UTI and started on Ciprofloxacin 250mg po BID. Pharmacist reviews the C&S at 48 hours per CPA protocol

**Pharmacist action:**
- De-escalate antibiotic by changing ciprofloxacin to amoxicillin 500mg Q 12H x 7 days

**Clinical benefits:**
- Negative outcomes prevented
  - Quinolone adverse drug reactions/use
  - Decreased risk of C. diff by de-escalation
  - Development of resistance
- Cost
  - What is it worth to prevent ER/hospital visit?
  - Prevention of C. diff requiring treatment
    - Risk for spreading infection high
What else do you need?

Procedures

- How does the pharmacist get notified?
  - Upon order for renal dose adjustments
  - Not all consultant pharmacist work for the dispensing pharmacy – you will need involvement from both

- When does the pharmacist get notified?
  - 48 hour antibiotic timeout is a good time to engage the pharmacist for antibiotic recommendations

Benefits to LTC

Optimizing antibiotic utilization will improve resident and facility outcomes

- Clinical outcomes
  - Reduced C. diff and adverse drug event rates
  - Increase CMS star rating
    - Potential to reduce re-hospitalization rates
    - Improved quality indicators and survey results
Wisconsin Healthcare-Associated Infections in LTC Coalition

Benefits to LTC

✔ Decrease Regulatory Risk
  • Required Antibiotic Stewardship Program in CMS “MegaRule”

✔ Medication Cost Savings
  • Formulary management
  • Decreased days of therapy

Wisconsin Healthcare-Associated Infections in LTC Coalition

Barriers to CPA

• Physician adoption
• Pharmacist adoption
• Nurse adoption

Most issues arise from lack of communication and understanding – show them how it works.
Barriers to Pharmacist Involvement

Consultant Pharmacists usually visit monthly
• Rarely have access to electronic medical records off-site and if so they are incomplete
• Software from the hospitals doesn't communicate with the nursing home software or the pharmacy software
• Education needed

Dispensing pharmacist may need additional training and resources to provide service.

Barriers to CPA

“When you're finished changing, you're finished” --Benjamin Franklin

“It is not the strongest or the most intelligent who will survive but those who can best manage change” --Charles Darwin
Pharmacist Return on Investment (ROI)\textsuperscript{15}

Estimated ROI of $1.29 per $1 in MTM administrative costs.

- Of 4849 patients not at goal when they enrolled in the plan, 55% of medical conditions improved and 23% remained the same following MTM services. When surveyed, 95.3% of respondents agreed or strongly agreed that their overall health and well-being had improved because of the pharmacist involvement.

Savings were more than 2.5 times the cost of the fees for pharmacists and network administration.

- Results from a Centers for Medicare and Medicaid Services demonstration project in Connecticut where nine pharmacists worked closely with 88 Medicaid patients from July 2009 through May 2010 revealed that pharmacists identified 917 drug therapy problems and resolved nearly 80% after four encounters, resulting in an annual savings of $1,123 per patient on medication claims and $472 per patient on medical, hospital, and emergency department expenses.
Generic drug use increased 9.8% and out of pocket expenditures decreased by 68%.

- A review was conducted for the 520 patients seen during one year at a pharmacist-directed medication therapy management program in a managed care setting. Study participants were low income elderly (avg. 78 yo) with multiple chronic medical conditions, multiple medications and high drug costs. A key finding was that 41% of total patients reported that they had or would soon discontinue drugs due to cost; 87% of these patients were able to continue or resume medication therapy as a result of the pharmacist interventions.

**Moving Pharmacy Forward**

- HR 592 (House of Representatives) and S.109 (Senate) Bills
- Pharmacy and medically underserved areas enhancement act
  - To amend title XVIII of the Social Security Act to provide for coverage under the Medicare program of pharmacist services.
- Reach out to your representatives requesting they support these bills
How to Start

• Embrace and encourage pharmacy involvement
  o LTC facilities have access to clinical/consultant pharmacists
  o Increasing trend of nurse practitioner model
    • Pharmacists and nurse practitioners can make a great team
• Raise the bar for your facility and pharmacist
• Scheduled a short meeting with your pharmacist during their next visit and share what you learned.
  o Tell them you will be implementing the When to Test Nursing Tool and you want them to help you ensure antibiotics used to treat UTIs at your facility are appropriate.

How to Start

• Start with the renal dosing CPA after you and your pharmacist have trained the nursing and CNA staff on when to test urine.
  o This might take awhile – don’t get discouraged.
  o Or, just go for it!
Wisconsin Healthcare-Associated Infections in LTC Coalition

References


